ArticleScientific reports2025
Small intestinal bacterial overgrowth as one of the diagnostic markers of hypertension.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
High blood pressure is one of the leading causes of premature death worldwide. Our previous study found that washed microbiota transplantation had a significant antihypertensive effect on patients with hypertension. This retrospective study was designed to assess the association between small intestinal bacterial overgrowth (SIBO) and hypertension. After primary intestinal disease was excluded, methane hydrogen breath test was used to diagnose intestinal bacterial overgrowth and the positive rate of SIBO was compared between hypertensive and non-hypertensive groups. The risk of SIBO occurrence from various related factors is analyzed comprehensively. After excluding secondary hypertension, compare the prevalence of hypertension in the SIBO + and SIBO - groups. Finally, the risk degree of the occurrence and development of hypertension was analyzed comprehensively. After excluding primary intestinal disease, 263 patients with hypertension and 480 patients without hypertension were enrolled. The positive rate of SIBO in hypertensive patients was significantly higher than that in non-hypertensive patients (49.00% vs. 37.50%, P = 0.002). Logistic regression adjusted for confounding factors, hypertension was a risk factor for positive SIBO (OR = 1.478, 95% CI: 1.039-2.102, P = 0.03). Excluding secondary hypertension, 333 patients with SIBO + group and 454 patients with SIBO - group were included. The prevalence of hypertension in SIBO + patients was significantly higher than that in SIBO - patients (41.10% vs. 31.50%, P = 0.005). The positive rate of SIBO in hypertensive patients is higher than that in non-hypertensive patients. The prevalence of hypertension in patients with positive SIBO is higher than that in patients with negative SIBO. The SIBO is closely related to hypertension, which can be as one of the diagnostic markers of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.